Loading...
Topical tirbanibulin resolves recalcitrant condyloma acuminata: Retrospective case series
Moore A. Y. Hurley K. Moore S. Moore L.
Moore A. Y.
Hurley K.
Moore S.
Moore L.
Citations
Altmetric:
Soloist
Composer
Publisher
Elsevier Inc.
Date
2023
Additional date(s)
Abstract
Condyloma acuminata (CA) are anogenital warts caused by human papillomavirus (HPV) infections. Currently, available treatments for CA include cryotherapy, imiquimod, sinecatechins, and podophyllotoxin. These topicals are limited by marked local skin reactions (LSRs), high recurrence rates, or limited accessibility. Clinical response of anogenital warts and HPV-16 (+) vulvar high-grade squamous intraepithelial lesions with topical tirbanibulin has been published recently. Tirbanibulin 1% ointment is a synthetic antiproliferative agent approved by the Food and Drug Administration in 2020 for the treatment of actinic keratoses as a once-daily topical treatment for 5 days. Tirbanibulin exhibits a dual mechanism of action, inhibiting microtubule polymerization by binding tubulin and disrupting Src kinase signaling in actively dividing cells. Here, we report real-world experience with topical tirbanibulin on CA in 5 patients.
Contents
Subject
clinical research
condyloma
drug response
general dermatology
genital warts
medical dermatology
Src kinase
tirbanibulin
condyloma
drug response
general dermatology
genital warts
medical dermatology
Src kinase
tirbanibulin
Subject(s)
Research Projects
Organizational Units
Journal Issue
Genre
Description
Format
Department
Burnett School of Medicine